Tag Archives: deficit

PBMs to Super Committee: Take $100 Billion From Pharma

A trade group representing the largest pharmacy benefits managers (PBMs) has proposed a way to trim $100 billion in government costs for prescription drugs over 10 years. To the pharmaceutical industry, that trim might look more like a beheading.
Posted in Marketing, Regulatory, Strategy, healthcare, leadership, pricing | Also tagged , , , , | 2 Comments

Pharma's Influence on the Super Committee: Is Cash Really King?

Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.
Posted in Strategy, healthcare, leadership | Also tagged , , , , , | 1 Comment

Does Pharma Have a Debt Crisis Strategy?

The Obama Administration’s proposed fiscal budget for 2012 suggested that all bets are off for biopharmaceutical revenue safeguards, but it never had a chance with Congress, as evidenced by a unanimous no-thank-you from the Senate in late May. But that was before debt ceiling talks and the alleged possibility of a default emerged as the [...]
Posted in Corporate Responsibility, Europe, Global, Strategy, healthcare, leadership, pricing | Also tagged , , , , | 1 Comment

Industry Reactions to Japan Earthquake Crisis

As a dazed Japan copes with the aftermath of the Tohoku earthquake, Japanese pharma companies have been quick to offer donations of both money and medical supplies and help with aid efforts. Takeda has pledged 300m Japanese Yen ($3.6m) to the Japanese Red Cross Society to help the emergency relief fund, as well as offering [...]
Posted in Global | Also tagged , , , , , | Leave a comment

The Potential Pain in Deficit Reduction

The US National Commission on Fiscal Responsibility’s draft report report signals US embrace of a fixed annual global budget for health care spending — experience in other countries suggests this will add to pressure for further cost controls on medicines beyond what is ordered up in Obamacare. Last week, Erskine Bowles and Alan Simpson, co-chairs for [...]
Posted in Regulatory, healthcare | Also tagged , , , , | 2 Comments